Use of platelet-rich growth factors for the treatment of temporomandibular joint degenerative disease: A prospective observational study

OBJECTIVE: To investigate the efficacy and safety of platelet-rich growth factors (PRGF® Endoret®) in adults with temporomandibular joint degenerative disease (TMJ-DJD) in a real-world clinical setting. MATERIALS AND METHODS: This prospective study included 67 adults with TMJ-DJD treated with two intra-articular PRGF® Endoret® infiltrations per affected joint, two weeks apart. Outcomes included pain, maximum mouth opening (with and without pain), crepitus, quality of life (OHIP-TMD), and adverse events. Assessments were performed at baseline and at 1 week, 1 month, 3 months, 6 months, and 1 year after the second infiltration. RESULTS: Forty-four patients completed follow-up. Pain decreased, while pain-free mouth opening and quality of life improved at all time points (p < .001). Mouth opening with pain improved at 1 year (p < .05). Crepitus was observed in 13-25% of patients. Most adverse events were mild and transient. CONCLUSIONS: PRGF® Endoret® infiltrations were associated with improved clinical outcomes and were well tolerated in patients with TMJ-DJD.